Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Phase 3 Recruiting 15 enrolled Amryt Pharma

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia

Timeline

Start: 2025-05-23
Primary completion: 2026-09-30
Completion: 2026-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metreleptin	Protein / enzyme biologic	—	Other

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Summary

Timeline

Drugs

Indications